Efficacy of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Real-World Practice in a Single Center

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China The authors have no conflicts of interest to declare. Consent to participate statement: For studies using human participants, written informed consent was obtained from participants to participate in the study. This study protocol was reviewed and approved by Institutional Ethics Committees of The First Affiliated Hospital, Zhejiang University School of Medicine, Approval Number (IIT20230282A). Hong Fang and Jianjun Qiao contributed equally to this work.